Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 11/20 | 0.59 |
| ▸ | PPARA | Q07869 | 11/20 | 0.59 |
| ▸ | PPARD | Q03181 | 5/20 | 0.55 |
| ▸ | SRR | Q9GZT4 | 4/20 | 0.50 |
| ▸ | PSAT1 | Q9Y617 | 2/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | CPA1 | P15085 | 1/20 | 0.47 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14392283 | 0.88 | PPARA (0.64) | PPARGPPARAPPARDCPA1 | |
| SCHEMBL5385471 | 0.88 | PPARA (0.74) | PPARGPPARAPPARD | |
| SCHEMBL5395182 | 0.85 | PPARA (0.81) | PPARGPPARAPPARD | |
| SCHEMBL3466702 | 0.84 | PPARA (0.56) | PPARGPPARAPPARDSRRPSAT1 | |
| SCHEMBL4451311 | 0.84 | PPARA (0.56) | PPARGPPARAPPARDSRRPSAT1 | |
| SCHEMBL4941128 | 0.84 | PPARA (0.56) | PPARGPPARAPPARDSRRPSAT1 | |
| SCHEMBL2517934 | 0.83 | SRR (0.70) | PPARGPPARAPPARDSRRPSAT1 | |
| SCHEMBL16877217 | 0.83 | SRR (0.70) | PPARGPPARAPPARDSRRPSAT1 | |
| SCHEMBL9628212 | 0.83 | SRR (0.70) | PPARGPPARAPPARDSRRPSAT1 | |
| SCHEMBL24328379 | 0.83 | PPARA (0.66) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399297-A1 | Novel Glutamine Analogs | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230399297-A1 | Novel Glutamine Analogs | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-12-14 | — | — | US | disclosed |
| WO-2022078416-A1 | NOVEL GLUTAMINE ANALOGS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399297-A1 | Novel Glutamine Analogs | GLUL, GATD3, GLS | PPARG 1211/4885PPARA 1857/4885PPARD 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.